Cheng Liyuan, Wang Jie, Wang Yicong, Li Jingjing, Yang Wenchao
College of Bee Science and Biomedicine, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
College of Food Science, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
Foods. 2025 Mar 14;14(6):996. doi: 10.3390/foods14060996.
Propolis demonstrates diverse pharmacological properties encompassing antimicrobial, anti-inflammatory, antioxidant, immunomodulatory, and wound-healing activities. This study investigated the therapeutic mechanism of propolis against ultraviolet (UV)-induced allergic dermatitis through an integrated approach combining network pharmacology with in vitro experimental validation. The targets of propolis components were conducted through the PubChem, the EMBL-EBI, and SEA Search Server databases, and the disease-associated targets for atopic dermatitis and related allergic conditions were extracted from GeneCards. The overlapping targets between propolis components and UV-induced dermatitis were screened. The Gene Ontology (GO) Enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed. The key targets were further validated through ELISA experiments using HSF cells. The results show that there were 28 overlapping targets between propolis and UV-induced allergic dermatitis. The GO enrichment results show that there were 1246 terms of biological functions, 52 terms of cellular components, and 98 terms of molecular functions. KEGG pathway enrichment obtained 110 signaling pathways. The protein-protein interaction (PPI) network showed that TNF, NFKB1, MMP-9, and IL-2 were hub proteins. The ELISA experiment confirmed that propolis reduced the levels of MMP-9 and IL-2 in UBV-induced allergic dermatitis of HSF cells in a dose-dependent manner. These findings provide mechanistic evidence supporting propolis as a promising functional food, dietary supplements, or medicinal agent for UV-induced allergic skin disorders.
蜂胶具有多种药理特性，包括抗菌、抗炎、抗氧化、免疫调节和伤口愈合活性。本研究通过网络药理学与体外实验验证相结合的综合方法，研究了蜂胶对紫外线（UV）诱导的过敏性皮炎的治疗机制。通过PubChem、EMBL-EBI和SEA搜索服务器数据库确定蜂胶成分的靶点，并从GeneCards中提取特应性皮炎和相关过敏病症的疾病相关靶点。筛选蜂胶成分与紫外线诱导性皮炎之间的重叠靶点。进行基因本体（GO）富集分析和京都基因与基因组百科全书（KEGG）通路富集分析。通过使用HSF细胞的ELISA实验进一步验证关键靶点。结果表明，蜂胶与紫外线诱导的过敏性皮炎之间有28个重叠靶点。GO富集结果显示，有1246个生物学功能术语、52个细胞成分术语和98个分子功能术语。KEGG通路富集获得110条信号通路。蛋白质-蛋白质相互作用（PPI）网络显示，TNF、NFKB1、MMP-9和IL-2是枢纽蛋白。ELISA实验证实，蜂胶以剂量依赖性方式降低了HSF细胞紫外线诱导的过敏性皮炎中MMP-9和IL-2的水平。这些发现为支持蜂胶作为紫外线诱导的过敏性皮肤疾病的有前景的功能性食品、膳食补充剂或药物提供了机制证据。
